$ARTV

RA CAPITAL MANAGEMENT, L.P. purchased $456K of ARTV (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. purchased 45,768 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $9.96 ($9.93–$9.99, $0.46M total) across 2 trades over 2026-07-29 to 2026-07-31.

Original reporting
SEC EDGAR · RA CAPITAL MANAGEMENT, L.P.
Published Jul 31, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
low confidence
Mentioned
$ARTV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The newest disclosed fact is the open-market purchase size, price range, and post-transaction share count. It does not include any operational or financial updates for Artiva.

02

Market read

Traders may note the disclosed buy as a positioning signal, but there is no accompanying catalyst that would justify a high-conviction trade.

03

What to watch

Indirect holdings and 10b5-1 status are not provided as a plan (explicitly says no pre-arranged 10b5-1), but without context on total position changes or investment mandate, the signal strength is uncertain.

Relevance 5/10Novelty 3/10Timing: filed 2026-07-31, covering purchases from 2026-07-29 to 2026-07-31

Background

The article is a SEC Form 4 insider transaction disclosure for Artiva Biotherapeutics (ARTV), reported by RA Capital Management, L.P. as a 10% owner with indirect holdings.

Company-level read

Ticker impact

$ARTVNeutralLow confidence
Context

RA Capital Management filed a Form 4 showing an indirect open-market purchase of 45,768 shares of Artiva Biotherapeutics at about $9.93 to $9.99.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional catalyst beyond positioning signal.

Evidence & confidence

The filing is a Form 4 for an indirect holding by a 10% owner, with no accompanying guidance, trial, deal, or regulatory event. Such transactions often have modest market impact unless tied to a broader corporate catalyst.

Market effects

Minimal; single-company Form 4 activity does not materially change biotech sector fundamentals.

None indicated.

None indicated.

Counterpoint

The purchase may reflect routine rebalancing or pre-existing exposure rather than a new bullish thesis, so price reaction may be muted.

Key entities

  • Artiva Biotherapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure (ARTV).

  • RA Capital Management, L.P.

    10% owner reporting an indirect open-market purchase of ARTV shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARTVMed

Artiva Biotherapeutics, Inc. (ARTV): Results of Operations and Financial Condition

Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®’s potential to drive deep B-cell depletion and meaningful clinical activity, with a